Journal article
Structural basis of transcription inhibition by fidaxomicin (lipiarmycin A3)
- Abstract:
-
Fidaxomicin is an antibacterial drug in clinical use for treatment of Clostridium difficile diarrhea. The active ingredient of fidaxomicin, lipiarmycin A3 (Lpm), functions by inhibiting bacterial RNA polymerase (RNAP). Here we report a cryo-EM structure of Mycobacterium tuberculosis RNAP holoenzyme in complex with Lpm at 3.5-Å resolution. The structure shows that Lpm binds at the base of the RNAP "clamp." The structure exhibits an open conformation of the RNAP clamp, suggesting that Lpm traps...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Accepted manuscript, pdf, 2.9MB)
-
- Publisher copy:
- 10.1016/j.molcel.2018.02.026
Authors
Funding
Bibliographic Details
- Publisher:
- Cell Press Publisher's website
- Journal:
- Molecular Cell Journal website
- Volume:
- 70
- Issue:
- 1
- Pages:
- 60-71.e15
- Publication date:
- 2018-03-28
- Acceptance date:
- 2018-02-23
- DOI:
- EISSN:
-
1097-4164
- ISSN:
-
1097-2765
- Pmid:
-
29606590
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
pubs:833421
- UUID:
-
uuid:6fed87e6-852f-4fa0-adaf-17531a31ebb8
- Local pid:
- pubs:833421
- Source identifiers:
-
833421
- Deposit date:
- 2018-04-05
Terms of use
- Copyright holder:
- Elsevier Inc
- Copyright date:
- 2018
- Notes:
- Copyright © 2018 Elsevier Inc. This is the accepted manuscript version of the article. The final version is available online from Cell Press at: https://doi.org/10.1016/j.molcel.2018.02.026
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record